TC
PBYI icon

TFS Capital’s Puma Biotechnology PBYI Stock Holding History

TFS Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,215
Closed -$212K – 1129
2016
Q1 		$212K Buy
+7,215
New +$326K 0.03% 746
2014
Q1 		– Sell
-4,315
Closed -$447K – 1523
2013
Q4 		$447K Sell
4,315
-359
-8% -$21.1K 0.02% 872
2013
Q3 		$251K Sell
4,674
-868
-16% -$46.8K 0.01% 1174
2013
Q2 		$246K Buy
+5,542
New +$195K 0.01% 1235

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

TFS Capital's PBYI Position: Q2 2016 in Review

TFS Capital sold out of Puma Biotechnology (PBYI) in Q2 2016, closing a stake of 7,215 shares — an estimated $212K sold.

TFS Capital first reported a position in PBYI in Q2 2013 and held it in 4 quarters. The position peaked at $447K in Q4 2013. 110 funds tracked by Wall St. Rank hold PBYI as of Q2 2016.

  • TFS Capital reported no remaining Puma Biotechnology position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 7,215 Puma Biotechnology shares in Q2 2016, an estimated $212K.
  • TFS Capital first reported a position in Puma Biotechnology in Q2 2013 and held it in 4 quarters.
  • TFS Capital's Puma Biotechnology position peaked at $447K in Q4 2013.
  • 110 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.